Novartis announced data from subgroup analyses of the three pivotal phase III MONALEESA trials showing that Kisqali (ribociclib) plus endocrine therapy extended progression-free survival compared to endocrine therapy alone, regardless of the presence of visceral metastases in pre-, peri- and postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
